Navigation Links
Early Switch to an Aromatase Inhibitor Increases Survival

For breast cancer patients taking tamoxifen, switching to an aromatase inhibitor within three years significantly improves survival rates//, according to a new study. The study reveals that the clear survival benefit was also achieved without an increased risk of death from other causes – a significant risk associated with tamoxifen.

Hormone modulating therapies have made a significant impact on the survival rates of women with estrogen-sensitive breast cancer over the last two decades. The drugs are used as adjuvant to primary surgical treatment for a period of five years.

Tamoxifen was the first estrogen modulator shown to increase survival and reduce the risk of breast cancer recurrence. However, tamoxifen is associated with increased risk of death from other causes, such as strokes and endometrial cancer. Despite this risk, tamoxifen and another drug in this class, raloxifene, remain an extensively used and popular treatment.

Aromatase inhibitors, such as aminoglutethimide and anastrozole, work in a different way to lower estrogen levels. Recent evidence shows aromatase inhibitors used alone or in follow-up after two years of tamoxifen therapy demonstrates clear and, in some cases, improved reduction of recurrence risk. However, there is conflicting evidence about mortality benefits.

Led by Professor Francesco Boccardo, M.D. of the National Cancer Research Institute and the University of Genoa in Italy, researchers pooled data from two studies (828 women) comparing five year treatment with tamoxifen alone (415 women) or tamoxifen for two to three years followed by an aromatase inhibitor for the remaining treatment period (413 women).

Dr. Boccardo and his colleagues found that compared to treatment with tamoxifen alone, all cause mortality risk and breast cancer-related mortality risk both fell significantly for women switching to an aromatase inhibitor. In addition, there was no increased risk of de ath from other causes in women who were prescribed the aromatase inhibitor.

"This pooled analysis provides solid evidence that switching to an aromatase inhibitor following a few years of tamoxifen treatment, implies a mortality benefit over continued tamoxifen and that the benefit on breast cancer-related mortality is mainly due to the effect of switching," conclude the authors.

Source-Eurekalert
'"/>




Related medicine news :

1. Early detection of prostate cancer
2. Early detection of heart attack
3. Early puberty linked to nutrition
4. Early Clue to Down Syndrome
5. Early delivery can prevent cancer
6. Early puberty more resistance
7. Early menopause- The cause
8. Early menopause- The cause
9. Early Warning System For Breast Cancer
10. Early therapy aids eyesight
11. Early detection of colorectal cancer may be hindered by coloured toilet disinfectants
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/26/2017)... , ... September 26, 2017 , ... “Sonflower Submission”: ... strong-willed nature to the inevitable destinations of negativity, complaining and the need to always ... to take effect in order for a lesson in stress-less living to be learned. ...
(Date:9/26/2017)... ... September 26, 2017 , ... “The Great Creator Saves Boobie and Ceebie”: a tool families ... Boobie and Ceebie” is the creation of published author, G.S. White, a devoted follower of ... in New Jersey. , “This book is not only for children but also to ...
(Date:9/25/2017)... ... September 25, 2017 , ... SignatureCare Emergency Center ... $1000 student scholarship is awarded each semester to a deserving student. Congratulations Ashlea! ... is a medical student at Arizona State University with a 3.63 GPA. Grabau ...
(Date:9/25/2017)... ... ... The Renal Support Network (RSN) is proud to announce the launch of ... focused on RSN’s mission to empower people who have kidney disease to become knowledgeable ... Our unique website is loaded with hundreds of exclusive personal stories. These posts are ...
(Date:9/25/2017)... ... 25, 2017 , ... FDAnews Expert Insight Series:, Device Regulation ... – 3:00 p.m. ET, http://www.fdanews.com/deviceregulation      , FDA Commissioner Scott ... short months:, ,     The first device recall over cybersecurity (a ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... 8, 2017 ... Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, September 18 th .The ... free MRI brain scans to the public.Where:  BTF,s ... at 501 K Street NW, Washington, D.C.What:BTF brings its nationwide initiative, the ...
(Date:9/7/2017)... , Sept. 7, 2017  Eli Lilly and ... actions to streamline operations to more efficiently focus ... its cost structure. Global workforce reductions, including those ... expected to impact approximately 3,500 positions. ... expects annualized savings of approximately $500 million that ...
(Date:9/7/2017)... , Sept. 7, 2017 NuvoAir ... Smart Spirometer, announced today a partnership with Novartis Pharma AG ... solidifies NuvoAir,s position as the leading mobile spirometry platform and ... patients. ... test ...
Breaking Medicine Technology: